Creative Commons source reading · ALS and frontotemporal degeneration
Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis.
Vlad A. Korben; Alexander K Lyashchenko; Beatriz Blanco-Redondo; Paymaan Jafar-Nejad; Neil A Shneider
Originally published in Nature medicine · 2022-01-24
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Fused in sarcoma (FUS) is an RNA-binding protein that is genetically and pathologically associated with rare and aggressive forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). To explore the mechanisms by which mutant FUS causes neurodegeneration in ALS-FTD, we generated a series of FUS knock-in mouse lines that express the equivalent of ALS-associated mutant FUSP525L and FUSΔEX14 protein. In FUS mutant mice, we show progressive, age-dependent motor neuron loss as a consequence of a dose-dependent gain of toxic function, associated with the insolubility of FUS and related RNA-binding proteins. In this disease-relevant mouse model of ALS-FUS, we show that ION363, a non-allele-specific FUS antisense oligonucleotide, efficiently silences Fus and reduces postnatal levels of FUS protein in the brain and spinal cord, delaying motor neuron degeneration. In a patient with ALS with a FUSP525L mutation, we provide preliminary evidence that repeated intrathecal infusions of ION363 lower wild-type and mutant FUS levels in the central nervous system, resulting in a marked reduction in the burden of FUS aggregates that are a pathological hallmark of disease.
Discussion
Since the initial discovery of ALS-associated mutations in FUS, attention has focused on the possibility that loss of one or more of the many functions of this essential regulatory protein in transcriptional regulation, pre-mRNA splicing, RNA processing and RNA localization might lead to selective neurodegeneration in ALS and FTD. Previous work in our group and others has argued that FUS-mediated toxicity is a not a consequence of FUS loss of function but, rather, a toxic gain of function related the disease-causing mutations.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
